Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.
Publication
, Journal Article
Smith, MA; Morton, CL; Kolb, EA; Gorlick, R; Keir, ST; Carol, H; Lock, R; Kang, MH; Reynolds, CP; Maris, JM; Watkins, AE; Houghton, PJ
Published in: Pediatr Blood Cancer
February 2010
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 microg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.
Duke Scholars
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
February 2010
Volume
54
Issue
2
Start / End Page
307 / 310
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Survival Analysis
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Pediatrics
- Oncology & Carcinogenesis
- Mice, SCID
- Mice, Inbred BALB C
- Mice
- Humans
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Smith, M. A., Morton, C. L., Kolb, E. A., Gorlick, R., Keir, S. T., Carol, H., … Houghton, P. J. (2010). Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer, 54(2), 307–310. https://doi.org/10.1002/pbc.22188
Smith, Malcolm A., Christopher L. Morton, E Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, et al. “Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.” Pediatr Blood Cancer 54, no. 2 (February 2010): 307–10. https://doi.org/10.1002/pbc.22188.
Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54(2):307–10.
Smith, Malcolm A., et al. “Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.” Pediatr Blood Cancer, vol. 54, no. 2, Feb. 2010, pp. 307–10. Pubmed, doi:10.1002/pbc.22188.
Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54(2):307–310.
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
February 2010
Volume
54
Issue
2
Start / End Page
307 / 310
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Survival Analysis
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Pediatrics
- Oncology & Carcinogenesis
- Mice, SCID
- Mice, Inbred BALB C
- Mice
- Humans
- Female